Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Non Communicable Diseases: COPD

3,872 views

Published on

Published in: Education, Health & Medicine
  • My brother found Custom Writing Service ⇒ www.HelpWriting.net ⇐ and ordered a couple of works. Their customer service is outstanding, never left a query unanswered.
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • ATTENTION! If You or Someone You Love is Suffering from Diabetes, Then This Will Be the Most Important Message You Will Ever Read... ♣♣♣ https://tinyurl.com/yx3etvck
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • What are the 5 foods that cause belly fat? ★★★ http://ishbv.com/bkfitness3/pdf
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here

Non Communicable Diseases: COPD

  1. 1. COPD WHAT IS IT?
  2. 2. Definition of COPDCOPD is a preventable and treatable disease with some significant extrapulmonary effects that may contribute to the severity in individual patients.Its pulmonary component is characterized by airflow limitation that is not fully reversible.The airflow limitation is usually progressive and associated with an abnormal inflammatory response of the lung to noxious particles or gases.
  3. 3. Disease Trajectory ofPatients with COPD Symptoms Exacerbations Exacerbations Deterioration Exacerbations End of Life
  4. 4. SYMPTOMS• The most common symptoms of COPD are breathlessness, or a need for air, excessive sputum production, and a chronic cough.• Others include wheezing, tiredness and chest tightness• However, COPD is not just simply a "smokers cough", but a under-diagnosed, life threatening lung disease that may progressively lead to death.• COPD develops slowly, it may take years before shortness of breath is noticed. Most of the time, COPD diagnosed among middle aged people 40 years old above
  5. 5. EPIDEMIOLOGY• According to the latest WHO estimates (2004), currently 64 million people have COPD and 3 million people died of COPD.• Prevalence and morbidity data greatlyunderestimate the total burden of COPD because the disease is usually not diagnosed until it is clinically apparent and moderately advanced.• In the Philippines, COPD is one of the 10 leading cause of death (DOH)
  6. 6. BURDEN• COPD is a leading cause of morbidity and mortality worldwide and results in an economicand social burden that is both substantial and increasing.• The burden of COPD is projected to increase in the coming decades due to continued exposure to COPD risk factors and the changing age structure of the world’s population.• Most of the information available on COPD prevalence, morbidity and mortality comes from high- income countries. Even in those countries, accurate epidemiologic data on COPD are difficult and expensive to collect. It is known that almost 90% of COPD deaths occur in low- and middle-income countries.
  7. 7. BURDEN• At one time, COPD was more common in men, but because of increased tobacco use among women in high-income countries and the higher risk of exposure to indoor air pollution (such as biomass fuel used for cooking and heating) in low-income countries, the disease now affects men and women almost equally.• In 2002 COPD was the fifth leading cause of death. Total deaths from COPD are projected to increase by more than 30% in the next 10 years unless urgent action is taken to reduce the underlying risk factors, especially tobacco use. Estimates show that COPD becomes in 2030 the third leading cause of death worldwide.
  8. 8. Burden of Tobacco Use• WB estimates in 1993 that global net social cost of smoking was US$200B each year. This huge economic burden is now shifting from developed to developing countries.• About 75% of todays tobacco users live on developing countries. By 2030, estimates are developing countries shall account to 70% of all tobacco deaths.• In Vietnam, tobacco spending 1.5x higher than education, 5x higher than health expenditure. Even homeless children in India spent significant portion of income purchasing tobacco.
  9. 9. Burden of Tobacco Use• In India, 1M die every year due to tobacco related diseases.• In the Philippines, researchers estimate total annual cost of illness for just four smoking related diseases - cerebrovascular diseases, coronary artery disease, COPD, and lung cancer - at US$2B, while real costs may be as high as US$6.05B each year.
  10. 10. Of the six leading causes of death in the United States, only COPD has been increasing steadily since 1970Source: Jemal A. et al. JAMA 2005
  11. 11. COPD Mortality by Gender, U.S., 1980-2000Number Deaths x 1000 70 60 50 Men 40 Women 30 20 10 0 1980 1985 1990 1995 2000 Source: US Centers for Disease Control and Prevention, 2002
  12. 12. COPD Mortality by Gender U.S., 1999-2006Between 1999and 2006,death rates forCOPD havedeclined amongU.S. men.There has beenno significantchange amongdeath ratesamong U.S.women. Source: US Centers for Disease Control and Prevention, 2011
  13. 13. RISK FACTORS
  14. 14. PRIMARY SUSPECT
  15. 15. Risk Factors for COPD  Genes  Lung growth and  Exposure to particles development  Tobacco smoke  Oxidative stress  Occupational dusts,  Gender organic and  Age inorganic  Indoor air pollution  Respiratory from heating and infections cooking with biomass  Socioeconomic in poorly ventilated status dwellings  Nutrition  Outdoor air pollution  Comorbidities
  16. 16. MANAGEMENT• An effective COPD management plan includes four components: – (1) assess and monitor disease; – (2) reduce risk factors; – (3) manage stable COPD; – (4) manage exacerbations.
  17. 17. Changes in Small Airways in COPD Patients Inflammatory exudate in lumen Disrupted alveolar attachments Thickened wall with inflammatory cells - macrophages, CD8+ cells, fibroblasts Peribronchial fibrosis Lymphoid follicle Source : Peter J. Barnes, MDPathogenesis, Pathology, Pathophysiology
  18. 18. Changes in the Lung Parenchyma in COPD Patients Alveolar wall destruction Loss of elasticity Destruction of pulmonary capillary bed ↑ Inflammatory cells macrophages, CD8+ lymphocytesSource : Peter J. Barnes,
  19. 19. Air Trapping in COPD Normal Mild/moderate Severe COPD COPDInspiration small airway alveolar attachments loss of elasticity loss of alveolar attachmentsExpiration closure ↓ Health Dyspnea Air trapping status ↓ Exercise capacity Hyperinflation Source : Peter J. Barnes,
  20. 20. DIAGNOSIS AND TREATMENT• COPD is confirmed by a simple diagnostic test called "spirometry" that measures how much air a person can inhale and exhale, and how fast air can move into and out of the lungs. Because COPD develops slowly, it is frequently diagnosed in people aged 40 or older.• COPD is not curable. Various forms of treatment can help control its symptoms and increase quality of life for people with the illness. For example, medicines that help dilate major air passages of the lungs can improve shortness of breath.
  21. 21. COPD and Co-morbiditiesCOPD patients are at increased risk for: • Myocardial infarction, angina • Osteoporosis • Respiratory infection • Depression • Diabetes • Lung cancer • Extrapulmonary (systemic) effects: Weight loss, Nutritional abnormalities, Skeletal muscle dysfunction
  22. 22. Diagnosis of COPD EXPOSURE TO RISK SYMPTOMS FACTORS cough tobacco sputum occupationshortness of breath indoor/outdoor pollution SPIROMETRY
  23. 23. Physical signs• Large barrel shaped chest (hyperinflation)• Prominent accessory respiratory muscles in neck and use of accessory muscle in respiration• Low, flat diaphragm• Diminished breath sound
  24. 24. Spirometry: Normal and Patients with COPDDiagnosisAssessing severityAssessing prognosisMonitoring progression
  25. 25. Classification of COPD Severity by Spirometry Stage I: Mild FEV1/FVC < 0.70 FEV1 > 80% predicted Stage II: Moderate FEV1/FVC < 0.70 50% < FEV1 < 80% predicted Stage III: Severe FEV1/FVC < 0.70 30% < FEV1 < 50% predicted Stage IV: Very Severe FEV1/FVC < 0.70 FEV1 < 30% predicted or FEV1 < 50% predicted plus chronic respiratory failureSPIROMETRY is not to substitute for clinical judgment in the evaluation of the severity of disease in individual patients.
  26. 26. Therapy at Each Stage of COPDI: Mild II: Moderate III: Severe IV: Very Severe Add long term oxygen if chronic respiratory failure. Consider surgery Add inhaled glucocorticosteroids if repeated exacerbations Add regular treatment with one or more long- acting bronchodilators* (when needed); Add rehabilitationActive reduction of risk factor(s); influenza vaccinationAdd short-acting bronchodilator (when needed) * ß2- agonists, anticholinergics and methylxanthines
  27. 27. LIMITATIONS1. The limited reach of individual and small group programs;2. Low penetration of programs to some segments of the population; and3. The desire to develop programs to achieve change in populations.
  28. 28. National collaborative approach to tobacco control issues,nominating a range of government, non-government andcommunity partnerships and linkages, under six keystrategy areas: • Strengthening community action • Promoting cessation of tobacco use • Reducing availability and supply of tobacco • Reducing tobacco promotion • Regulating tobacco; and • Reducing exposure to environmental tobacco smoke
  29. 29. – Agenda Setting– Increasing the salience of tobacco control issues– Facilitating acceptance of tobacco control policy initiatives to achieve structural change– Behaviour change– Increased preparedness to quit– Prompting quit action– Prompting supportive action for quitters– Providing reinforcement for ex-smokers and never smokers.
  30. 30. TOBACCO INDUSTRY• Massive infrastructure• Billion dollar budgets• Ingenious product marketing
  31. 31. ANTI- TOBACCO INDUSTRY• Quit campaigns • Fragmented• Health departments - infrastructure State/Territory and • Cooperative rather than Commonwealth coordinated approach• Cancer councils • Limited funding• National Heart • Smokers targeted Foundation through multiple• Action on Smoking and approaches with varying Health research to support• Peak medical bodies• Quitline• Pharmaceutical companies
  32. 32. % of smokers 10,0 20,0 30,0 40,0 50,0 60,0 0,0 R U S G EO C H N AR G G ER PH I AU T SU I PO L C ZE BR A KO R N ED JP N M E X SY RCountry U SA U K PO R N O R R SA Percent of Smokers M A L IT A KG Z TH A AU S C AN SW E SI N
  33. 33. In Asia, most men smoke1) CHN 70,2 %2) RUS 63,0 %3) GEO 57,5 %4) SYR 46,0 %5) JPN 43,3 %6) KGZ 41,4 %
  34. 34. In Europe, most women smoke1) BRA 30,0 %2) RUS 30,0 %3) NED 28,0 %4) CZE 28,0 %5) GER 28,0 %6) AUT 26,0 %
  35. 35. Warning labels on cigarette packs Are available in all surveyed countries! But: No COPD warning in most countries!Except: NOR, CZE, USA, CAN, JPN, THA, AUS, RSA
  36. 36. Smoking can damage health• Is known throughout all countries• But smoke of indoor heating and cooking with biomass fuels is not recognized to be harmful!
  37. 37. Awareness in % 0,0 100,0 10,0 20,0 30,0 40,0 50,0 60,0 70,0 80,0 90,0 ITA NOR NED SWE AUS AUT GER CAN POL SUI CZE UK USA JPN CHNCountry THA SYR PHI MAL POR BRA KGZ GEO RSA RUS MEX Awareness of COPD is low in public ARG SIN KOR
  38. 38. Patients don’t seek help• Smokers showing symptoms of COPD like – Coughing, – Sputum production – Shortness of breath• Smokers do not relate these signs to smoking or COPD• And do not seek medical treatment
  39. 39. GPs generally do not diagnose ortreat COPD• The awareness of COPD among GPs is quite high• The opinion of the interviewed ICC members revealed that only few GPs would diagnose COPD• As a consequence, GPs do normally not treat COPD• Only in Austria, Italy, The Netherlands and Canada, more than 80 % of GPs will diagnose and treat COPD
  40. 40. % of GPs with spirometer 0 10 20 30 40 50 60 70 80 90 KO R AU T AU S SU I PO L G ER C AN JP N N ED U K M E X PO R N O R SW E SI N AR GCountry IT A U SA R SA R U S PH I M A L C ZE BR A TH A C H N KG Z G EO Most GPs do not have access to spirometry SY R
  41. 41. Not in all countries treatment costs willbe covered by health insurances •In most of the developed countries, health insurances •No full coverage in Mexico, Argentina, Brazil, Russia, •Large population can’t afford treatment
  42. 42. Huge information about COPD isavailable• In nearly all surveyed countries COPD patient organizations exist• Guidelines for diagnosis and treatment exist• The GOLD guidelines are mainly known by specialists• Many GPs don’t know the GOLD guidelines or don’t follow them
  43. 43. Biggest Unmet Needs• Awareness among patients about disease and risk factors (e.g. smoking)• Lack of smoking cessation programs• More anti-smoking campaigns are needed (TV etc.)• Need for a better approach to prevention and treatment of cigarette smoking• Lack of early diagnosis• Huge number of undiagnosed/untreated COPD patients• Diagnosis among GPs (spirometry needed)• Differentiation between asthma and COPD unclear to many GPs• Treatment algorithms are not followed/known by GPs• No proper disease management by GPs• Lack of rehabilitation facilities• Funding of all drugs needed for treatment• Lack of lung specialists• More access to oxygen therapy• Governmental programs to fight COPD
  44. 44. Public• Percentage of smokers is too high• More effective anti-smoking campaigns are needed• Raise public awareness of COPD• Drive patients with symptoms to GPs• Enable smoking cessation programs
  45. 45. Physicians• Increase knowledge regarding diagnosis, treatment and management of COPD among GPs• Follow GOLD guidelines• Spirometry is needed• More rehabilitation centres needed• More specialists needed
  46. 46. Government• Increase coverage for medical treatment• Make medications available for poor patients• Smoking bans in public areas needed• COPD labeling on cigarette packs needed
  47. 47. Environment: Behavioral: Economic Smoking Cessation Diagnosis (Spirometric confirma Health seeking transport and work Rehabilitation PolicyDepression/ helplessness Healthcare organization diet tobacco physical activity COPD Access to Support groups Govt/ Community Programs Education/ Advertising Medication Availability Non Modifiable: Age, Sex, Genes
  48. 48. Better outcomes for Chronic Conditions
  49. 49. Further Readings• Global Initiative for Chronic Obstructive Lung Disease. Spirometry for Healthcare Providers. (2007)• Manual of Pulmonary Function Testing. Gregg l. Ruppel. Ninth Edition.• Interpretation of Pulmonary Function Tests. Robert E. Hyatt. Second Edition• Burden of Obstructive Lung Disease (BOLD) and participated in by the COPD Foundation of the Philippines and the COPD Council of the Philippine College of Chest Physicians

×